Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T85670
(Former ID: TTDI02219)
|
|||||
Target Name |
Nerve growth factor (NGF)
|
|||||
Synonyms |
NGFB; Beta-nerve growth factor; Beta-NGF
|
|||||
Gene Name |
NGF
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 4 Target-related Diseases | + | ||||
1 | Chronic pain [ICD-11: MG30] | |||||
2 | General pain disorder [ICD-11: 8E43] | |||||
3 | Osteoarthritis [ICD-11: FA00-FA05] | |||||
4 | Pain [ICD-11: MG30-MG3Z] | |||||
Function |
Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems. Extracellular ligand for the NTRK1 and NGFR receptors, activates cellular signaling cascades to regulate neuronal proliferation, differentiation and survival (Probable). The immature NGF precursor (proNGF) functions as ligand for the heterodimeric receptor formed by SORCS2 and NGFR, and activates cellular signaling cascades that lead to inactivation of RAC1 and/or RAC2, reorganization of the actin cytoskeleton and neuronal growth cone collapse. In contrast to mature NGF, the precursor form (proNGF) promotes neuronal apoptosis (in vitro) (By similarity). Inhibits metalloproteinase-dependent proteolysis of platelet glycoprotein VI. Binds lysophosphatidylinositol and lysophosphatidylserine between the two chains of the homodimer. The lipid-bound form promotes histamine relase from mast cells, contrary to the lipid-free form (By similarity).
Click to Show/Hide
|
|||||
BioChemical Class |
Growth factor
|
|||||
UniProt ID | ||||||
Sequence |
MSMLFYTLITAFLIGIQAEPHSESNVPAGHTIPQAHWTKLQHSLDTALRRARSAPAAAIA
ARVAGQTRNITVDPRLFKKRRLRSPRVLFSTQPPREAADTQDLDFEVGGAAPFNRTHRSK RSSSHPIFHRGEFSVCDSVSVWVGDKTTATDIKGKEVMVLGEVNINNSVFKQYFFETKCR DPNPVDSGCRGIDSKHWNSYCTTTHTFVKALTMDGKQAAWRFIRIDTACVCVLSRKAVRR A Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
HIT2.0 ID | T83QHM |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 8 Clinical Trial Drugs | + | ||||
1 | Fasinumab | Drug Info | Phase 3 | Neuropathic pain | [2] | |
2 | Tanezumab | Drug Info | Phase 3 | Neuropathic pain | [2] | |
3 | SAR164877 | Drug Info | Phase 2/3 | Pain | [3] | |
4 | CERE-110 | Drug Info | Phase 2 | Alzheimer disease | [4] | |
5 | CXB-909 | Drug Info | Phase 1/2 | Neurodegenerative disorder | [5] | |
6 | ABT-110 | Drug Info | Phase 1 | Chronic pain | [6] | |
7 | MEDI-578 | Drug Info | Phase 1 | Pain | [7] | |
8 | NsG-0202 | Drug Info | Phase 1 | Alzheimer disease | [8] | |
Discontinued Drug(s) | [+] 1 Discontinued Drugs | + | ||||
1 | Nerve growth factor | Drug Info | Terminated | Alzheimer disease | [9] | |
Mode of Action | [+] 2 Modes of Action | + | ||||
Inhibitor | [+] 2 Inhibitor drugs | + | ||||
1 | Fasinumab | Drug Info | [2] | |||
2 | Tanezumab | Drug Info | [2] | |||
Modulator | [+] 7 Modulator drugs | + | ||||
1 | SAR164877 | Drug Info | [1] | |||
2 | CERE-110 | Drug Info | [10] | |||
3 | CXB-909 | Drug Info | [11] | |||
4 | ABT-110 | Drug Info | [1], [12] | |||
5 | MEDI-578 | Drug Info | [1] | |||
6 | NsG-0202 | Drug Info | [11] | |||
7 | Nerve growth factor | Drug Info | [13] |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-interacting Proteins |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Fate of novel painkiller mAbs hangs in balance.Nat Biotechnol.2011 Mar;29(3):173-4. | |||||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 3 | ClinicalTrials.gov (NCT02447276) Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip. U.S. National Institutes of Health. | |||||
REF 4 | ClinicalTrials.gov (NCT00876863) Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health. | |||||
REF 5 | ClinicalTrials.gov (NCT01505907) Pharmacokinetic Study of CXB909 in Healthy Male Subjects. U.S. National Institutes of Health. | |||||
REF 6 | ClinicalTrials.gov (NCT00941746) Safety and Tolerability of PG110 in Patients With Knee Osteoarthritis Pain. U.S. National Institutes of Health. | |||||
REF 7 | Clinical pipeline report, company report or official report of MedImmune (2011). | |||||
REF 8 | ClinicalTrials.gov (NCT01163825) Encapsulated Cell Biodelivery of Nerve Growth Factor to Alzheimer Disease Patients. U.S. National Institutes of Health. | |||||
REF 9 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000658) | |||||
REF 10 | CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther. 2010 Apr;12(2):240-7. | |||||
REF 11 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||||
REF 12 | Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists Drugs.2014 Apr;74(6):619-26. | |||||
REF 13 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.